These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37030072)

  • 21. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hereditary Ovarian Cancer and Risk Reduction.
    Andrews L; Mutch DG
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():31-48. PubMed ID: 28254144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
    Loizzi V; Cicinelli E; Del Vecchio V; Arezzo F; Deromemaj X; Kardhashi A; Paradiso A; Legge F; Natalicchio MI; Resta L; Resta N; Loconte DC; Cormio G
    Acta Biomed; 2022 Aug; 93(4):e2022051. PubMed ID: 36043985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
    Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
    J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR; Kauff ND; Domchek SM
    J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience.
    Nagashima M; Ishikawa T; Asami Y; Hirose Y; Shimada K; Miyagami S; Mimura T; Miyamoto S; Onuki M; Morioka M; Izumi M; Yoshida R; Yamochi T; Taruno K; Nakamura S; Sekizawa A; Matsumoto K
    Jpn J Clin Oncol; 2023 Jun; 53(6):472-479. PubMed ID: 36999211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
    Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
    J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
    Rabban JT; Krasik E; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Dec; 33(12):1878-85. PubMed ID: 19898224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.
    Kim HY; Park J; Moon SJ; Jeong S; Hong JH; Lee JK; Cho GJ; Cho HW
    Cancer Res Treat; 2024 Jan; 56(1):143-148. PubMed ID: 37591780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
    Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome.
    Wright JD; Silver ER; Tan SX; Hur C; Kastrinos F
    JAMA Netw Open; 2021 Sep; 4(9):e2123616. PubMed ID: 34499134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy.
    Manchanda R; Silvanto A; Abdelraheim A; Burnell M; Johnson M; Saridogan E; Rosenthal AN; Brunell C; Aslam N; Vashisht A; Pandis G; Jacobs I; Menon U; Benjamin E
    Int J Gynecol Cancer; 2012 Jun; 22(5):881-8. PubMed ID: 22572844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
    Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
    Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
    Cummings S; Roman SS; Saam J; Bernhisel R; Brown K; Lancaster JM; Usha L
    J Ovarian Res; 2021 Apr; 14(1):61. PubMed ID: 33926482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
    Shu CA; Pike MC; Jotwani AR; Friebel TM; Soslow RA; Levine DA; Nathanson KL; Konner JA; Arnold AG; Bogomolniy F; Dao F; Olvera N; Bancroft EK; Goldfrank DJ; Stadler ZK; Robson ME; Brown CL; Leitao MM; Abu-Rustum NR; Aghajanian CA; Blum JL; Neuhausen SL; Garber JE; Daly MB; Isaacs C; Eeles RA; Ganz PA; Barakat RR; Offit K; Domchek SM; Rebbeck TR; Kauff ND
    JAMA Oncol; 2016 Nov; 2(11):1434-1440. PubMed ID: 27367496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
    Seppälä TT; Dominguez-Valentin M; Crosbie EJ; Engel C; Aretz S; Macrae F; Winship I; Capella G; Thomas H; Hovig E; Nielsen M; Sijmons RH; Bertario L; Bonanni B; Tibiletti MG; Cavestro GM; Mints M; Gluck N; Katz L; Heinimann K; Vaccaro CA; Green K; Lalloo F; Hill J; Schmiegel W; Vangala D; Perne C; Strauß HG; Tecklenburg J; Holinski-Feder E; Steinke-Lange V; Mecklin JP; Plazzer JP; Pineda M; Navarro M; Vida JB; Kariv R; Rosner G; Piñero TA; Pavicic W; Kalfayan P; Ten Broeke SW; Jenkins MA; Sunde L; Bernstein I; Burn J; Greenblatt M; de Vos Tot Nederveen Cappel WH; Della Valle A; Lopez-Koestner F; Alvarez K; Büttner R; Görgens H; Morak M; Holzapfel S; Hüneburg R; von Knebel Doeberitz M; Loeffler M; Redler S; Weitz J; Pylvänäinen K; Renkonen-Sinisalo L; Lepistö A; Hopper JL; Win AK; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Therkildsen C; Wadt KAW; Mourits MJE; Ketabi Z; Denton OG; Rødland EA; Vasen H; Neffa F; Esperon P; Tjandra D; Möslein G; Rokkones E; Sampson JR; Evans DG; Møller P
    Eur J Cancer; 2021 May; 148():124-133. PubMed ID: 33743481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
    Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
    Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.